Strategic Operations Intern (Summer 2026) jobs in United States
cer-icon
Apply on Employer Site
company-logo

Lonza · 14 hours ago

Strategic Operations Intern (Summer 2026)

positionUS - Portsmouth, NH
timeInternship
remoteOnsite
seniorityIntern
workcardStart in 2026 Summer

Lonza is one of the world’s leading suppliers to the pharmaceutical and biotech markets, and they are seeking a Strategic Operations Intern for their 2026 On-site Summer Internship program. The intern will assist the strategic operations team in driving manufacturing safety, quality, cost, and delivery improvement projects while ensuring documentation accuracy and supporting new equipment implementation.

BiotechnologyLife SciencePharmaceutical

Responsibilities

Helping to drive manufacturing safety, quality, cost, and delivery improvement projects with the assistance of the strategic operations team
Ensuring that the documents (Work Instructions; SOPs; Batch Records) are accurate and easy to understand
Assisting with new equipment implemented in the asset

Qualification

Research skillsProject managementAttention to detailVerbal communicationWritten communicationSelf-motivationTeam collaboration

Required

Completion of junior year (typically 90 credits) towards a B.S. degree in a related field
Minimum cumulative GPA of 3.0 (out of 4) required
Must currently be enrolled in BS or MS Academic Program
Must be available to begin the Internship on Tuesday, May 26, 2026
Excellent verbal and written communications skills
Self-motivation and the ability to contribute as a team member
Ability to organize, plan and execute projects
Research skills and attention to detail

Benefits

Onsite cafeteria
Fitness center
Other amenities

Company

Lonza

twittertwittertwitter
Glassdoor3.6
company-logo
Lonza Group supplies products and services to pharmaceutical and agrochemical industries.
dateFounded in 1897
location
Basel, Basel-Stadt, CHE
people-size10001+ employees
web-link
http://www.lonza.com

Funding

Current Stage
Public Company
Total Funding
$444.8M
2023-11-06Post Ipo Debt· $444.8M
2020-12-07IPO

Leadership Team

leader-logo
Wolfgang Wienand
Chief Executive Officer
linkedin
leader-logo
Alfons Ehinger
Founder

Recent News

NH Business Review
2026 BOB Award winners
2026-01-17
GlobeNewswire
Exosome Research Market Projected to Reach US$ 2,491.42 Million by 2035, Supported by Expanding Therapeutic Development Pipelines | Astute Analytica
2026-01-15
PR Newswire
Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
2026-01-07
Company data provided by crunchbase